Sajan Shyaula| Cardiovascular Disease | Best Researcher Award

Best Researcher Award

Sajan Shyaula
Nepal Academy of Science and Technology

Sajan Shyaula
Affiliation Nepal Academy of Science and Technology
Country Nepal
Scopus ID 54917556500
Documents 29
Citations 242
h-index 8
Subject Area Cardiovascular Disease
Event International Research Awards on Cardiology & Cardiovascular Medicine

Sajan Shyaula is a researcher affiliated with the Nepal Academy of Science and Technology whose indexed scholarly profile is associated with Cardiovascular Disease. The available bibliographic record reports 29 documents, 242 citations, and an h-index of 8. These indicators provide a quantitative basis for describing his research activity and scholarly visibility. [1]

Abstract

Sajan Shyaula is a researcher affiliated with the Nepal Academy of Science and Technology and associated with the subject area of Cardiovascular Disease. His indexed research profile records 29 documents, 242 citations, and an h-index of 8. These bibliometric indicators provide a quantitative description of his scholarly activity and citation visibility. Cardiovascular research encompasses investigation into disease mechanisms, epidemiology, prevention, diagnosis, and treatment, requiring multidisciplinary scientific approaches. Assessment of a researcher in this field may consider publication activity, citation influence, methodological quality, scientific relevance, and sustained contribution. Shyaula’s documented profile provides a basis for further academic evaluation within cardiovascular research. [1]

Keywords

Sajan Shyaula, Best Researcher Award, Cardiovascular Disease, cardiovascular research, cardiology, cardiovascular medicine, Nepal Academy of Science and Technology, Scopus, research impact, scholarly publications, citation analysis, h-index.

Introduction

Cardiovascular Disease is a broad research field encompassing the study of cardiovascular conditions, their risk factors, prevention, diagnosis, and treatment. Cardiovascular research draws upon clinical science, epidemiology, biomedical investigation, and translational approaches. Bibliometric indicators such as publications, citations, and h-index can provide useful quantitative context when assessing scholarly activity, although they should be interpreted alongside the quality and significance of individual research contributions. [2]

Research Profile

The available Scopus profile identifies Sajan Shyaula with Author ID 54917556500 and associates the researcher with the Nepal Academy of Science and Technology. The indexed record contains 29 documents and reports 242 citations, with an h-index of 8. These figures indicate a documented body of scholarly output and measurable citation activity within the indexed research literature. [1]

Research Contributions

Research contributions in cardiovascular science may involve clinical investigation, disease characterization, epidemiological analysis, cardiovascular risk assessment, diagnostic research, therapeutic evaluation, or evidence synthesis. The available bibliographic information confirms Shyaula’s research activity in Cardiovascular Disease, while detailed claims about particular discoveries or methodologies require examination of the underlying publications. A publication-level assessment can therefore complement the quantitative indicators reported by bibliographic databases.

Publications

The indexed profile reports 29 documents associated with Sajan Shyaula. This publication record forms the bibliographic basis for evaluating his research activity. Interpretation of the publication portfolio should consider authorship, journal characteristics, study design, methodological rigor, research relevance, and citation context. Publication quantity alone does not establish the scientific importance of individual studies or the overall quality of a researcher’s contributions. [1]

Research Impact

The reported 242 citations and h-index of 8 provide quantitative measures of the citation visibility of Shyaula’s indexed research. The h-index was introduced as a measure combining publication productivity with citation impact and is now widely used as one component of research assessment. [3] Citation indicators can vary according to discipline, publication age, collaboration patterns, and database coverage, so they are most appropriately considered together with qualitative evidence.

Award Suitability

The documented research profile presents several factors relevant to consideration for a Best Researcher Award, including a defined cardiovascular research area, an institutional affiliation, 29 indexed documents, 242 citations, and an h-index of 8. These indicators provide a quantitative foundation for academic review. A comprehensive award assessment should additionally consider originality, methodological rigor, relevance to cardiovascular medicine, independent contribution, research quality, and broader scholarly significance.

Conclusion

Sajan Shyaula’s available indexed profile documents an established research record associated with Cardiovascular Disease and the Nepal Academy of Science and Technology. The reported 29 documents, 242 citations, and h-index of 8 provide measurable evidence of scholarly activity and citation visibility. These indicators support further evaluation of his research contributions for recognition within cardiovascular research and medicine. [1]

References

  1. Elsevier. (n.d.). Scopus Author Details: Sajan Shyaula, Author ID 54917556500. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=54917556500
  2. Research article (2026. ) Quantitative determination of combination of amlodipine besylate and telmisartan in tablets using 1H-qNMR and its comparison to HPLC for further validation.
    https://doi.org/10.1016/j.cpan.2026.03.010
  3. World Health Organization. (2026 ). Cardiovascular diseases. World Health Organization.
    https://cardiology-conferences.pencis.com/

Yu Tian | Cardiac immunology | Best Researcher Award

Dr. Yu Tian, Jiangsu University, China

Dr. Yu Tian is a prominent researcher at Jiangsu University, China, specializing in immunology and molecular biology. With a focus on immune cell migration, viral myocarditis, and neuroinflammation, Dr. Tian has contributed significantly to understanding immune responses in cardiovascular and neurological diseases. He has published numerous articles in prestigious journals such as Journal of Leukocyte Biology and International Immunopharmacology, and his research explores therapeutic targets like HMGB1 and IL-22. Dr. Tian’s work plays a critical role in advancing treatment strategies for diseases involving immune system dysfunction and inflammation.

Profile:
Education:

 

Dr. Yu Tian completed his Bachelor’s Degree in Medicine at Qinghai University from September 2011 to June 2016. He then pursued his Master’s and Ph.D. at Jiangsu University, School of Medicine, from September 2016 to September 2022, where he specialized in immunology and molecular biology. His academic journey has laid a strong foundation for his research in immune cell function and disease mechanisms, contributing to his current role as a researcher at Jiangsu University.

Professional Experience:

 

Dr. Yu Tian is currently a researcher at Jiangsu University, School of Life Sciences, specifically within the International Genomics Research Center, a position he has held since December 2022. In this role, he leads a horizontal research project investigating the effects of HMGB1 on immune cells, which commenced in 2023. Additionally, Dr. Tian is actively involved in a National Natural Science Foundation of China (NSFC)-funded project that examines the role of IGF-1 in heart damage following myocardial infarction, scheduled for 2025 to 2027. His work contributes significantly to advancing the understanding of immune mechanisms in cardiovascular health.

 

Research Interest:

 

Dr. Yu Tian’s research interests lie in immunology, specifically investigating the role of HMGB1 in immune cell responses. He focuses on cardiovascular diseases, exploring the mechanisms that contribute to heart damage and myocardial infarction. Additionally, Dr. Tian studies adipose tissue accumulation and its impact on worsening heart conditions, aiming to uncover potential therapeutic targets for improving cardiovascular health. His work seeks to enhance the understanding of immune and metabolic interactions in the context of heart disease.

Conclusion:

Dr. Yu Tian is an accomplished researcher at Jiangsu University, specializing in immunology and cardiovascular diseases. With a solid educational background and a focus on the role of HMGB1 in immune responses, he is dedicated to unraveling the complex mechanisms underlying heart damage and myocardial infarction. His ongoing research projects aim to deepen the understanding of immune cell interactions and metabolic factors that exacerbate cardiovascular conditions. Through his contributions, Dr. Tian is poised to make a significant impact on the field, advancing potential therapeutic strategies for improving heart health and addressing related diseases.

Top Notable Publications:

Yin, P., Su, Z., Shu, X., Dong, Z., Tian, Y. (2024). Role of TREM2 in immune and neurological diseases: Structure, function, and implications. International Immunopharmacology, 143, 113286. 0 citations

Tian, Y., Gong, X., Qin, D., Liu, F., Su, Z. (2023). S1PR1-dependent migration of ILC3s from intestinal tissue to the heart in a mouse model of viral myocarditis. Journal of Leukocyte Biology, 114(2), 154–163. 7 citations

Tian, Y., Chen, R., Su, Z. (2023). HMGB1 is a Potential and Challenging Therapeutic Target for Parkinson’s Disease. Cellular and Molecular Neurobiology, 43(1), 47–58. 6 citations

Chen, R., Liu, F., Xia, L., Xu, H., Su, Z. (2022). B10 cells decrease fibrosis progression following cardiac injury partially by IL-10 production and regulating hyaluronan secretion. Journal of Leukocyte Biology, 111(2), 415–425. 1 citation

Cao, Y., Tian, Y., Liu, Y., Su, Z. (2022). Reg3β: A Potential Therapeutic Target for Tissue Injury and Inflammation-Associated Disorders. International Reviews of Immunology, 41(2), 160–170. 2 citations

Che, Y., Tian, Y., Chen, R., Liu, F., Su, Z. (2021). IL-22 ameliorated cardiomyocyte apoptosis in cardiac ischemia/reperfusion injury by blocking mitochondrial membrane potential decrease, inhibiting ROS and cytochrome C. Biochimica et Biophysica Acta – Molecular Basis of Disease, 1867(9), 166171. 26 citations

Chen, W., Yao, S., Wan, J., Yao, Y., Zhang, X. (2021). BBB-crossing adeno-associated virus vector: An excellent gene delivery tool for CNS disease treatment. Journal of Controlled Release, 333, 129–138. 45 citations

Li, J., Xia, L., Liu, F., Chen, R., Su, Z. (2021). lncRNA187415.1 silence in BCAMs ameliorated breast cancer progression by blocking C/EBPβ-lncRNA187415.1-CISH axis and reversing pro-tumor characteristic of BCAMs. Clinical and Translational Medicine, 11(5), e407. 1 citation

Huang, L., Wan, J., Wu, Y., Su, Z., Xu, H. (2021). Challenges in adeno-associated virus-based treatment of central nervous system diseases through systemic injection. Life Sciences, 270, 119142. 26 citations

Wan, J., Wu, Y., Huang, L., Wang, S., Xu, H. (2021). ILC2-derived IL-9 inhibits colorectal cancer progression by activating CD8+ T cells. Cancer Letters, 502, 34–43. 31 citations